Ketamine in Refractory Status Epilepticus: Clinical Evidence and Therapeutic Implications

Ahmad Rizky Pratama, Siti Nur Aisyah and Muhammad Fajar Hidayat
Additional contact information
Ahmad Rizky Pratama: Department of Neurology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
Siti Nur Aisyah: Department of Neurology, Faculty of Medicine, Universitas Gadjah Mada, Dr. Sardjito General Hospital, Yogyakarta, Indonesia
Muhammad Fajar Hidayat: Department of Neurology, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

International Journal of Neurology, 2023, vol. 57, 70

Abstract: Refractory status epilepticus remains one of the most challenging neurological emergencies in clinical practice, carrying high rates of morbidity and mortality and posing a significant risk of permanent neurological damage. Despite the widespread use of conventional antiepileptic drugs and anesthetic agents, a substantial proportion of patients fail to achieve adequate seizure control, highlighting the need for alternative therapeutic approaches that target different pathophysiological mechanisms. In this context, ketamine has gained increasing attention as a potential treatment option for refractory and superrefractory status epilepticus. The aim of this study was to review and synthesize the available evidence regarding the use of ketamine in the management of refractory status epilepticus, with particular focus on its mechanism of action, clinical effectiveness, and practical implications for neurological care. A systematic review of the literature was conducted, including studies that evaluated the administration of ketamine in adult patients with refractory or superrefractory status epilepticus. The selected studies comprised a variety of designs, including retrospective analyses, prospective registries, case series, and narrative reviews. The evidence indicates that ketamine has been associated with partial or complete seizure control in a considerable proportion of patients, especially when introduced early during the course of refractory status epilepticus. Its non-competitive antagonism of N-methyl-D-aspartate (NMDA) receptors allows modulation of sustained glutamatergic hyperexcitability, a key mechanism underlying seizure persistence when GABAergic therapies become less effective. In addition, ketamine demonstrated a favorable hemodynamic profile and a low incidence of severe adverse effects in critically ill neurological patients. Overall, the findings suggest that ketamine represents a valuable therapeutic option in refractory status epilepticus and support its consideration within individualized treatment strategies, while further prospective studies are needed to better define optimal dosing, timing, and patient selection.

Keywords: refractory status epilepticus; ketamine; NMDA receptors; epilepsy; neuroprotection (search for similar items in EconPapers)
Date: 2023
References: Add references at CitEc
Citations:

Downloads: (external link)
https://ijneurology.org/index.php/ijn/article/view/70 Abstract page (text/html)
https://ijneurology.org/index.php/ijn/article/download/70/138 Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cwh:ijneur:v:57:y:2023:id:70

DOI: 10.62486/ijn202370

Access Statistics for this article

More articles in International Journal of Neurology from International Journal of Neurology
Bibliographic data for series maintained by Dr. Andrew Alberto López Sánchez ().